What Is Pneumonia, and Why Is It More Common in Cancer Patients?

What Is Pneumonia?

Pneumonia is infectious or noninfectious lung inflammation (drug-related pneumonitis/ILD, radiation pneumonitis).

Cancer treatments, neutropenia and hospital exposure increase risk.

Early diagnosis and distinguishing “infection or pneumonitis?” are important. Early treatment is also lifesaving.

Why Does It Matter?

Pneumonia is a leading cause of emergency visits and intensive care admissions in cancer patients. After chemotherapy, days 7–14 neutropenia, mucositis/aspiration, central catheters, prolonged admission and COPD, diabetes or malnutrition increase risk. Some anticancer drugs cause noninfectious pneumonitis/ILD , which can resemble infection. Respiratory symptoms must therefore be rapidly assessed as “microbial pneumonia or drug-related pneumonitis?” .

The practical approach has three pillars: (1) Early stabilization (oxygen, sepsis bundle), (2) Rapid diagnostic sampling and imaging (cultures, viral PCR, chest CT), (3) Empirical treatment (appropriate antibiotics for infection; drug withdrawal + steroids for pneumonitis). In severe immunosuppression, consider opportunists such as PJP, Aspergillus and CMV.

• Microbial invasion: Bacteria/viruses/fungi colonize and proliferate in alveoli.
• Impaired host defenses: Neutropenia/lymphopenia, steroids, anti-CD20, barrier damage.
• Drug-related inflammation (pneumonitis): T-cell inflammation with checkpoint inhibitors; toxic/hypersensitivity patterns with some TKIs/ADCs/mTORi.

Fever, dry/productive cough, dyspnea, chest pain, tachypnea, low oxygen and weakness. Opportunistic PJP/CMV may cause fever-dry cough-hypoxemia; drug pneumonitis typically causes exertional dyspnea and diffuse CT ground-glass changes.

• Fever: 38.0°C or higher or chills, particularly after chemotherapy on days 7–14 .
• Dyspnea: Worse at rest/speaking, inability to climb stairs, SpO₂ < 94% or a substantial drop from baseline.
• Rapid Breathing/Chest Pain: Respiratory rate ≥22/min, stabbing or pleuritic pain.
• Persistent/worsening cough or purulent green/brown sputum, rusty sputum/hemoptysis.
• Confusion, marked weakness, inability to drink, reduced urine.
• During Immunotherapy/TKI/ADC: New dyspnea/cough; suspected diffuse CT ground-glass changes.
• After Radiotherapy: Cough/dyspnea/fever within the RT field.
• High-Risk Groups: 65+, COPD, heart failure, diabetes, kidney failure, prolonged steroids; seek care earlier in these groups.

Emergency Warnings: SpO₂ ≤ 90%, severe dyspnea, blue lips, severe chest pain or altered consciousness → 112 / emergency department.

1. Initial hours: Vital signs, SpO₂; rapid fluids + oxygen + antibiotics for suspected sepsis.
2. Laboratory: CBC, CRP, PCT, lactate; PCT may be low in immunosuppression.
3. Imaging: Chest X-ray; if uncertain, chest CT (consolidation versus diffuse ground-glass).
4. Microbiology: Blood/sputum cultures; pneumococcal/Legionella urinary antigens; nasopharyngeal viral PCR. In immunosuppression, serum β-D-glucan, galactomannan.
5. Bronchoscopy/BAL: For suspected PJP/CMV/Aspergillus or pneumonitis differentiation.
6. Medication review: ICI, EGFR/ALK TKI, mTORi, ADC or RT in the past 3–6 months?

1. Stabilization: Oxygen, high-flow if needed; sepsis bundle.
2. Empirical Treatment (Evidence of Infection):
   • Community-acquired, moderate/severe: β-lactam (ampicillin-sulbactam/ceftriaxone) + macrolide or respiratory fluoroquinolone.
   • Hospital/neutropenic risk: Antipseudomonal β-lactam (piperacillin-tazobactam/meropenem/cefepime) ± MRSA coverage (vancomycin/linezolid) ± dual Gram-negative coverage as appropriate.
   • Suspected PJP: High-dose TMP-SMX; steroids for hypoxemia. Infectious disease consultation for CMV/Aspergillus.
3. Suspected Drug-Related Pneumonitis: The suspected agent should be stopped. According to CTCAE:
   • G1: Close monitoring ± temporary interruption.
   • G2: Prednisone ~1 mg/kg/day, taper over 10–14 days; hold ICI.
   • G3–4: Methylprednisolone 1–2 mg/kg/day IV; ICI: discontinue. If no response within 48 hours, consider MMF/IVIG/infliximab* after excluding infection.

   *Infliximab: Multidisciplinary decision after tuberculosis/infection screening.

4. Support: Respiratory physiotherapy, bronchodilators when needed, nutrition, early mobilization.
5. Monitoring and De-escalation: Clinical/CRP response at 48–72 hours; narrow treatment according to cultures.

• Outpatient CAP: High-dose amoxicillin or doxycycline; macrolide according to local resistance.
• In Hospital: β-lactam + macrolide or respiratory fluoroquinolone; Pseudomonas/MRSA coverage with risk factors.
• Neutropenic Pneumonia: Antipseudomonal β-lactam ± MRSA; add antifungal/antiviral if needed.
• PJP: TMP-SMX (TMP 15–20 mg/kg/day), divided into 3–4 doses; steroids for hypoxemia.
• CMV/Aspergillus: Ganciclovir / voriconazole, etc.; specialist consultation.
• Drug-Related Pneumonitis: Steroid-based treatment + criteria for resumption; high vigilance with T-DXd.

• Vaccines: Annual influenza; pneumococcal (PCV20 or PCV15→PPSV23), COVID-19 boosters.
• PJP Prophylaxis: For ≥20 mg/day prednisone-equivalent for ≥4 weeks, alemtuzumab, temozolomide+RT and similar regimens, TMP-SMX.
• Drug and RT Planning: Early CT threshold and close symptom screening with high-ILD-risk agents (EGFR TKI, T-DXd).
• Lifestyle: Smoking cessation, reduce aspiration risk through feeding/positioning practices; swallowing therapy if needed.

For most cancer patients, pneumococcal vaccination is recommendedbecause immunosuppression and hospital exposure increase the risk of pneumococcal pneumonia, sepsis and meningitis . See our article for detailed information.

1. IDSA/ATS Adult Community-Acquired Pneumonia Guidelines; IDSA Febrile Neutropenia/Infection Management.
2. NCCN Prevention and Treatment of Cancer-Related Infections; Management of Immunotherapy-Related Toxicities.
3. ASCO/ESMO consensus documents on immune-related adverse event (irAE) management.
4. ESMO CPG: Anticancer treatment-associated pneumonitis/ILD (EGFR/ALK TKI, mTORi, ADC, ICI).
5. Practice statements on trastuzumab deruxtecan (T-DXd)-associated ILD management.
6. ERS/ATS guidelines for interstitial lung disease and opportunistic pneumonias (PJP, CMV, aspergillosis).